Latest News

CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

GUILFORD, Conn.–(BUSINESS WIRE)–First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative

Source link

Related posts

Uganda says a traveling Congolese girl has Ebola


Possible treatment for rare polio-like illness shows no benefit


HPRA issues new advice on HIV self-test kits


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy